[HTML][HTML] A phase 3 trial of bevacizumab in ovarian cancer
TJ Perren, AM Swart, J Pfisterer… - … England Journal of …, 2011 - Mass Medical Soc
Background Angiogenesis plays a role in the biology of ovarian cancer. We examined the
effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women …
effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women …
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
…, J Herod, G McCluggage, M Parmar, AM Swart - The Lancet, 2015 - thelancet.com
Background The international standard of care for women with suspected advanced ovarian
cancer is surgical debulking followed by platinum-based chemotherapy. We aimed to …
cancer is surgical debulking followed by platinum-based chemotherapy. We aimed to …
[HTML][HTML] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 …
…, A Poveda, GC Jayson, D Stark, AM Swart… - The Lancet …, 2015 - thelancet.com
Background The ICON7 trial previously reported improved progression-free survival in women
with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the …
with ovarian cancer with the addition of bevacizumab to standard chemotherapy, with the …
[HTML][HTML] Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup
…, DG Mutch, RA Burger, AM Swart… - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Purpose To determine if incorporation of an additional cytotoxic agent improves overall
survival (OS) and progression-free survival (PFS) for women with advanced-stage epithelial …
survival (OS) and progression-free survival (PFS) for women with advanced-stage epithelial …
[HTML][HTML] Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
…, C Mediola, C Coens, W Qian, MKB Parmar, AM Swart - The Lancet, 2010 - thelancet.com
Background Serum CA125 concentration often rises several months before clinical or
symptomatic relapse in women with ovarian cancer. In the MRC OV05/EORTC 55955 …
symptomatic relapse in women with ovarian cancer. In the MRC OV05/EORTC 55955 …
[HTML][HTML] Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial
…, D Stark, E Clark, L Farrelly, AM Swart… - The Lancet, 2016 - thelancet.com
Background Angiogenesis is a validated clinical target in advanced epithelial ovarian
cancer. Cediranib is an oral antiangiogenic vascular endothelial growth factor receptor 1–3 …
cancer. Cediranib is an oral antiangiogenic vascular endothelial growth factor receptor 1–3 …
[HTML][HTML] Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 …
…, T Ehlen, GC Jayson, N Johnson, AM Swart… - The Lancet …, 2018 - thelancet.com
Background Individual patient data from two randomised trials comparing neoadjuvant
chemotherapy with upfront debulking surgery in advanced tubo-ovarian cancer were analysed to …
chemotherapy with upfront debulking surgery in advanced tubo-ovarian cancer were analysed to …
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms …
…, MS Carey, P Beale, W Qian, AM Swart… - The lancet …, 2013 - thelancet.com
Background In the Gynecologic Cancer Intergroup International Collaboration on Ovarian
Neoplasms 7 (ICON7) trial, bevacizumab improved progression-free survival in patients with …
Neoplasms 7 (ICON7) trial, bevacizumab improved progression-free survival in patients with …
[HTML][HTML] Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free …
…, RM Glasspool, R Jones, S Williams, AM Swart… - The Lancet, 2019 - thelancet.com
Background Carboplatin and paclitaxel administered every 3 weeks is standard-of-care first-line
chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a …
chemotherapy for epithelial ovarian cancer. The Japanese JGOG3016 trial showed a …
Speeding up the evaluation of new agents in cancer
…, N James, MA Bookman, AM Swart… - Journal of the …, 2008 - academic.oup.com
Despite both the increase in basic biologic knowledge and the fact that many new agents
have reached various stages of development during the last 10 years, the number of new …
have reached various stages of development during the last 10 years, the number of new …
